Zoledronic Acid Markedly Improves Bone Mineral Density for Patients with Monoclonal Gammopathy of Undetermined Significance and Bone Loss

MLA

Donald Woytowitz, et al. “Zoledronic Acid Markedly Improves Bone Mineral Density for Patients with Monoclonal Gammopathy of Undetermined Significance and Bone Loss.” Clinical Cancer Research, vol. 14, Sept. 2008, pp. 6289–95. EBSCOhost, https://doi.org/10.1158/1078-0432.ccr-08-0666.

APA

Donald Woytowitz, Siu Fun Wong, Ori Yellin, Marshall S. Flam, Olcay Batuman, Herbert Duvivier, Regina A. Swift, Ralph V. Boccia, Mehdi M. Moezi, Youram Nassir, & James R. Berenson. (2008). Zoledronic Acid Markedly Improves Bone Mineral Density for Patients with Monoclonal Gammopathy of Undetermined Significance and Bone Loss. Clinical Cancer Research, 14, 6289–6295. https://doi.org/10.1158/1078-0432.ccr-08-0666

Chicago

Donald Woytowitz, Siu Fun Wong, Ori Yellin, Marshall S. Flam, Olcay Batuman, Herbert Duvivier, Regina A. Swift, et al. 2008. “Zoledronic Acid Markedly Improves Bone Mineral Density for Patients with Monoclonal Gammopathy of Undetermined Significance and Bone Loss.” Clinical Cancer Research 14 (September): 6289–95. doi:10.1158/1078-0432.ccr-08-0666.